Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab »

Bevacizumab: An Immune Therapy in Mesothelioma Treatment

Bevacizumab An Immune Therapy in Mesothelioma Treatment

Bevacizumab, an immune therapy, enhances the immune system to target cancer cells. Historically, chemotherapy drugs were considered the standard treatment. But, a new study highlights bevacizumab, an immune therapy. It can now be considered in combination with mesothelioma treatments where accessible. Chemotherapy has been a popular treatment therapy. Cytotoxic chemotherapy uses anti-cancer (cytotoxic) drugs to destroy cancer cells. It results in a modest improvement in patient survival. But toxicity limits the eligible patient population. Targeted Chemotherapy Agents Immunotherapies are now playing a greater role in the treatment of many cancers. The last decade has presented a paradigm shift. There has been a change in the way we understand the relationship between the immune system and cancer progression. Several targeted agents … Continue reading Bevacizumab: An Immune Therapy in Mesothelioma Treatment »

Mesothelioma Surveillance Protocols, Quality of Life, and Patient Hope

Mesothelioma Surveillance Protocols, Quality of Life, and Patient Hope

Mesothelioma surveillance protocols are a series of medical tests. Surveillance is designed to detect and track cancer progression. Surveillance protocols also check treatment effectiveness. And they provide patients with reassurance and hope. A new study identified the effectiveness of mesothelioma surveillance protocols. This study focused on patients who have noncurative treatment intent. Importance of Reassurance and Hope Findings from nine different studies identified the need for reassurance and hope as part of surveillance. They also highlighted the importance of trust and relationships. Follow-up and surveillance models provide patients with continuity, reassurance, and updates on condition. Continuity ensured patients knew who to contact if they had a new symptom or concern. Patient hopes for follow-up were for management of pain and … Continue reading Mesothelioma Surveillance Protocols, Quality of Life, and Patient Hope »

Research Advancements Audit by Asbestos Diseases Research Institute

Research Advancements Audit by Asbestos Diseases Research Institute

Research advancements provide a brighter future for malignant pleural mesothelioma patients. Pleural mesothelioma is an aggressive cancer of the lung lining. Mesothelioma is associated with asbestos exposure. Australian researchers from the Asbestos Diseases Research Institute and the University of Sydney have reviewed the basic research advancements. Their new publication covers mesothelioma biomarkers and treatment strategies. There is a long latency period from asbestos exposure to cancer development. A lack of genetic biomarkers makes early diagnosis difficult. The prognosis of pleural mesothelioma is poor. There is an average survival of eight to fourteen months following diagnosis. Diagnostic Biomarkers Biomarkers are limited in the clinic to diagnose pleural mesothelioma. A biomarker is a biological molecule found in blood or other body fluids … Continue reading Research Advancements Audit by Asbestos Diseases Research Institute »

Asbestos Cement Roofing Poses an Ongoing Risk for Mesothelioma

asbestos cement roofing

Australian researchers have a warning for people in homes with asbestos cement roofing: Replace your roof or risk mesothelioma in the future.  Michael Kottek and Man Lee Yuen are with the Asbestos Diseases Research Institute in Sydney. They recently published a new report on the risk of mesothelioma from roof tiles made of asbestos.  Like all asbestos-containing products, asbestos cement roofing breaks down over time. Disintegrating or “friable” asbestos is the number one cause of deadly malignant mesothelioma worldwide.  Writing in the American Journal of Industrial Medicine, Kottek and Yuen say buildings with roofs made from asbestos pose an ongoing threat to occupants, even if the tiles are not disturbed.  Asbestos-Containing Products and Asbestos Cancer There was a time when … Continue reading Asbestos Cement Roofing Poses an Ongoing Risk for Mesothelioma »

Genetic Mesothelioma Risk May Lead to Shorter Latency

genetic mesothelioma risk

A particular genetic risk for mesothelioma may be behind the few cases where cancer develops just a few years after asbestos exposure. That is the word from researchers at Australia’s Flinders University and the Asbestos Diseases Research Institute.  Latency is the time it takes after exposure to a cancer-causing agent for signs of cancer to show up. Malignant mesothelioma has one of the longest latency periods of any cancer. In most cases, it takes about 40 years for mesothelioma to develop. As a result, mesothelioma is rare in people under 65. But, in rare cases, mesothelioma develops earlier in life. These cases have sometimes been dismissed as being unrelated to asbestos. But in a new journal article, mesothelioma experts from … Continue reading Genetic Mesothelioma Risk May Lead to Shorter Latency »

New Mesothelioma Grading System: A Better Path to Prognosis?

mesothelioma grading system

A team of Australian researchers have developed a new mesothelioma grading system they believe is a more accurate method for predicting outcomes. The system assigns weighted scores based on things like mesothelioma subtype, the shape of the nuclei, BAP1 loss and other parameters. A higher score suggests the patient’s mesothelioma case may be more challenging to treat. Tests of the system in more than 350 patients show that it is highly accurate.  The team lays out their new mesothelioma grading system in a recent issue of the American Journal of Surgical Pathology. In the article, they make the case for why this new prognostic tool could be a helpful supplement to the current, more widely-used WHO system.  The Importance of … Continue reading New Mesothelioma Grading System: A Better Path to Prognosis? »

Aussie Campaign Warns of Mesothelioma Risk for Homeowners

mesothelioma risk for homeowners

An ad campaign launched by Australia’s top asbestos awareness organization has issued a warning about the mesothelioma risk for homeowners doing renovations.  Asbestos is the number one cause of mesothelioma around the world. Australia has a long history with both asbestos and mesothelioma. The country banned asbestos in 2003 but there is still plenty of it around. Thousands of homes and buildings built before 1990 contain asbestos.  There is a mesothelioma risk for homeowners who come in contact with this asbestos. Mesothelioma is an aggressive and deadly cancer that can kill within months of diagnosis.  If people remodel or attempt renovations without having their home checked for asbestos first, the campaign says they are playing “renovation roulette” with their lives.  … Continue reading Aussie Campaign Warns of Mesothelioma Risk for Homeowners »

Mesothelioma Clinical Trials: Eligibility May Be Too Strict, Study Finds

mesothelioma clinical trials

A new Australian study suggests that too many people are being left out of mesothelioma clinical trials under current trial rules.  The researchers say that eligibility requirements around pleural mesothelioma studies are too strict. The result is that many people never have the opportunity to take advantage of investigational treatments only available through studies.  In addition, the trial data gathered may not really apply to average mesothelioma patients. The Australian researchers are calling for changes that will let more people qualify for mesothelioma clinical trials.  What Are Mesothelioma Clinical Trials? Pleural mesothelioma is an intractable cancer of the lining around the lungs. People who get it usually worked in an industry that exposed them to asbestos. Once asbestos gets in … Continue reading Mesothelioma Clinical Trials: Eligibility May Be Too Strict, Study Finds »

Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma

phase 3 clinical trial

A potential new first-line immunotherapy treatment for mesothelioma is now recruiting patients for a phase 3 clinical trial. The trial will compare the immunotherapy drug durvalumab (IMFINZI) combined with chemotherapy against chemotherapy alone.  Results from the phase 2 trials of this combination released last year were promising. Tests showed that it extended mesothelioma survival by about 8 months with no debilitating side effects.  The randomized phase 3 clinical trial will try to confirm these results in a larger group of people. Mesothelioma Treatment with Durvalumab Durvalumab is an immune checkpoint inhibitor. Immune checkpoint inhibitors deactivate a cancer cell survival mechanism that helps cancer cells evade the immune system. Pleural mesothelioma and other types of cancer use proteins like PD-1 to … Continue reading Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma »

Get your free copy of
“Surviving Mesothelioma” Today!